Related Experiment Video
Updated: Jun 3, 2026

08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma
Xiaofeng Liao1, Chen Li1, Ming Huang1
1Department of General Surgery, Jiangning Hospital, Hushan Road NO.169, Nanjing, Jiangsu, China.
Scientific Reports
|June 1, 2026
Summary
Conditional survival analysis reveals improving survival rates for malignant peritoneal mesothelioma (MPM) patients over time. Chemotherapy shows potential survival benefits, and a new nomogram aids individualized risk assessment for this rare cancer.
Area of Science:
- Oncology
- Biostatistics
- Epidemiology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer with poor prognosis and limited treatment options.
- Low incidence hinders large-scale studies on survival outcomes and treatment impact, necessitating advanced analytical methods.
Purpose of the Study:
- To apply conditional survival (CS) analysis to assess survival trends in MPM patients.
- To explore the survival benefits of chemotherapy using propensity score matching (PSM).
- To develop and validate a nomogram for CS prediction in MPM.
Main Methods:
- Conditional survival (CS) analysis on SEER data (2000-2019) for 1,549 MPM patients.
- Machine learning algorithms (Random Survival Forest, LASSO regression) and Cox models for nomogram development.
- Propensity score matching (PSM) to evaluate chemotherapy's effect on survival.
Main Results:
- CS rates improved with time post-diagnosis, indicating a need for early intervention.
- The CS-based nomogram showed strong predictive performance (C-index: 0.701 training, 0.717 validation).
- PSM analysis suggested chemotherapy is associated with improved overall survival in MPM patients.
Conclusions:
- CS analysis offers a time-updated survival estimate, aiding patient counseling and follow-up strategies.
- The CS-based nomogram provides a valuable tool for individualized risk assessment in MPM.
- Chemotherapy may offer survival benefits, warranting further investigation for MPM treatment optimization.

